{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:41:51Z","timestamp":1790476911968,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Mitsubishi Tanabe Pharma Corporation and AstraZeneca K.K"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.molmet.2018.10.009","type":"journal-article","created":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T02:17:20Z","timestamp":1540606640000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels"],"prefix":"10.1016","volume":"19","author":[{"given":"Takayoshi","family":"Suga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1364-9565","authenticated-orcid":false,"given":"Osamu","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Yokota-Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8041-1915","authenticated-orcid":false,"given":"Tsutomu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazusane","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-7093","authenticated-orcid":false,"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2018.10.009_bib1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrendo.2015.51","article-title":"Islet\u00a0alpha cells and glucagon--critical regulators of energy homeostasis","volume":"11","author":"Campbell","year":"2015","journal-title":"Nature Reviews Endocrinology"},{"key":"10.1016\/j.molmet.2018.10.009_bib2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2337\/diab.36.3.274","article-title":"Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics","volume":"36","author":"Baron","year":"1987","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.10.009_bib3","first-page":"4053","article-title":"Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus","volume":"85","author":"Shah","year":"2000","journal-title":"The Journal of Cinical Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib4","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1210\/me.2010-0120","article-title":"Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice","volume":"24","author":"Hancock","year":"2010","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.molmet.2018.10.009_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2018.10.009_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00125-006-0511-1","article-title":"Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells","volume":"50","author":"Vieira","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2018.10.009_bib7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2337\/diabetes.54.6.1789","article-title":"Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells","volume":"54","author":"Ravier","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.10.009_bib8","doi-asserted-by":"crossref","first-page":"14389","DOI":"10.1074\/jbc.M109.069195","article-title":"Glucose suppression of glucagon secretion: metabolic and calcium responses from alpha-cells in intact mouse pancreatic islets","volume":"285","author":"Le Marchand","year":"2010","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.molmet.2018.10.009_bib9","doi-asserted-by":"crossref","first-page":"8971","DOI":"10.1074\/jbc.270.15.8971","article-title":"Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization","volume":"270","author":"Heimberg","year":"1995","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.molmet.2018.10.009_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Natura Medica"},{"key":"10.1016\/j.molmet.2018.10.009_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mam.2012.11.002","article-title":"Glucose transport families SLC5 and SLC50","volume":"34","author":"Wright","year":"2013","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.molmet.2018.10.009_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2018.10.009_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2018.10.009_bib14","doi-asserted-by":"crossref","first-page":"31214","DOI":"10.1038\/srep31214","article-title":"Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells","volume":"6","author":"Pedersen","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.molmet.2018.10.009_bib15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJMcibr1506573","article-title":"Type 2 diabetes, SGLT2 inhibitors, and glucose secretion","volume":"373","author":"Hattersley","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2018.10.009_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.tem.2015.05.011","article-title":"SGLT-2 inhibition and glucagon: cause for alarm?","volume":"26","author":"Kibbey","year":"2015","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.diabet.2017.04.002","article-title":"Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells","volume":"43","author":"Solini","year":"2017","journal-title":"Diabetes and Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.10.009_bib19","doi-asserted-by":"crossref","first-page":"E1225","DOI":"10.1152\/ajpendo.00507.2013","article-title":"Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity","volume":"306","author":"Ueta","year":"2014","journal-title":"American Journal of Physiology Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/diabetes.52.5.1147","article-title":"A\u00a0novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line","volume":"52","author":"Gribble","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.10.009_bib21","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00125-012-2585-2","article-title":"Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion","volume":"55","author":"Parker","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2018.10.009_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2337\/db14-0807","article-title":"Molecular mechanisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine","volume":"64","author":"Kuhre","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.10.009_bib23","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.2337\/db17-0058","article-title":"Mechanisms controlling glucose-induced GLP-1 secretion in human small intestine","volume":"66","author":"Sun","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.10.009_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.10.009_bib25","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.2337\/db15-0022","article-title":"Reduction in SGLT1 mRNA expression in the ventromedial hypothalamus improves the counterregulatory responses to hypoglycemia in recurrently hypoglycemic and diabetic rats","volume":"64","author":"Fan","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.10.009_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.phrs.2016.07.001","article-title":"Pharmacological aspects of the safety of gliflozins","volume":"118","author":"Faillie","year":"2017","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.molmet.2018.10.009_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1530\/EJE-13-0941","article-title":"Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans","volume":"170","author":"Bak","year":"2014","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.molmet.2018.10.009_bib28","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1007\/s00216-017-0534-0","article-title":"Accurate analytical method for human plasma glucagon levels using liquid chromatography-high resolution mass spectrometry: comparison with commercially available immunoassays","volume":"409","author":"Miyachi","year":"2017","journal-title":"Analytical and Bioanalytical Chemistry"},{"key":"10.1016\/j.molmet.2018.10.009_bib29","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1128\/MCB.21.16.5624-5630.2001","article-title":"Preserved pancreatic beta-cell development and function in mice lacking the insulin receptor-related receptor","volume":"21","author":"Kitamura","year":"2001","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.molmet.2018.10.009_bib30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3389\/fnins.2016.00502","article-title":"Sweet taste receptor serves to activate glucose- and leptin-responsive neurons in the hypothalamic arcuate nucleus and participates in glucose responsiveness","volume":"10","author":"Kohno","year":"2016","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.molmet.2018.10.009_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"The Journal of Clinical Pharmacology"},{"key":"10.1016\/j.molmet.2018.10.009_bib32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","article-title":"Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cmet.2016.08.020","article-title":"Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes","volume":"24","author":"Segerstolpe","year":"2016","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2337\/diab.26.5.445","article-title":"A\u00a0test of the hypothesis that the rate of fall in glucose concentration triggers counterregulatory hormonal responses in man","volume":"26","author":"DeFronzo","year":"1977","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2018.10.009_bib35","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00125-008-1149-y","article-title":"Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas","volume":"51","author":"de Heer","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2018.10.009_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cmet.2010.04.007","article-title":"GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis","volume":"11","author":"De Marinis","year":"2010","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib37","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2018.10.009_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbrc.2017.08.031","article-title":"Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet","volume":"492","author":"Hira","year":"2017","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.molmet.2018.10.009_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.molmet.2018.05.011","article-title":"Altered pancreatic islet morphology and function in SGLT1 knockout mice on a glucose-deficient, fat-enriched diet","volume":"13","author":"Muhlemann","year":"2018","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib40","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/dom.12898","article-title":"Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomized, double-blind, placebo-controlled trial","volume":"19","author":"Kadowaki","year":"2017","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib41","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2018.10.009_bib42","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2018.10.009_bib43","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2018.10.009_bib44","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2018.10.009_bib45","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2018.10.009_bib46","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1507\/endocrj.EJ15-0396","article-title":"Effect of dapagliflozin on colon cancer cell [Rapid Communication]","volume":"62","author":"Saito","year":"2015","journal-title":"Endocrine Journal"},{"key":"10.1016\/j.molmet.2018.10.009_bib47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/hepr.12856","article-title":"Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus","volume":"47","author":"Sumida","year":"2017","journal-title":"Hepatology Research"},{"key":"10.1016\/j.molmet.2018.10.009_bib48","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00000658-199803000-00011","article-title":"Effect of glucagon on protein synthesis in human rectal cancer in situ","volume":"227","author":"Hartl","year":"1998","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.molmet.2018.10.009_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ijc.2910300112","article-title":"Growth responses of rat stomach cancer cells to gastro-entero-pancreatic hormones","volume":"30","author":"Kobori","year":"1982","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.molmet.2018.10.009_bib50","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/0002-9610(85)90406-4","article-title":"Glucagon enhances growth of cultured human colorectal cancer cells in\u00a0vitro","volume":"150","author":"Moyer","year":"1985","journal-title":"Americas Journal of Surgery"},{"key":"10.1016\/j.molmet.2018.10.009_bib51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/joim.12462","article-title":"Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia","volume":"279","author":"Junker","year":"2016","journal-title":"Journal of Internal Medicine"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877818309372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877818309372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T08:15:28Z","timestamp":1546589728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877818309372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":51,"alternative-id":["S2212877818309372"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2018.10.009","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2018.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}